[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"intracerebral-haemorrhage-ich\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:intracerebral-haemorrhage-ich":33},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,62,104],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":25,"conditions":26,"keywords":34,"overallStatus":49,"whyStopped":4,"lastUpdateSubmitDate":50,"lastUpdatePostDateStruct":51,"startDateStruct":54,"completionDateStruct":56,"leadSponsor":58,"locationsCount":61},"100611166","phase-2-minocycline-in-stroke-study-at-maimonides-100611166",false,"NCT07237048","Minocycline in Stroke Study at Maimonides","Effect of Oral Minocycline in Patients With Acute Stroke - a Randomized, Open Label, Prospective Trial","\\* Inclusion criteria\n\nIn order to be eligible to participate in this study, an individual must meet all of the following criteria:\n\n1. Age \\>\u002F=18\n2. NIHSS 5-20 \\*National Institutes of Health Stroke Scale\\*\n3. Acute onset neurological deficit consistent with acute ischemic stroke or on imaging consistent with acute ischemia as defined by WHO \\*(World Health Organization) \\* guidelines or acute onset of neurological deficits with intracerebral Hemorrhage on imaging consistent with intracerebral bleed\n4. The onset of neurological symptoms less than 24 hours\n\n   * Exclusion criteria\n\nAn individual who meets any of the following criteria is excluded from participation in this study:\n\n1. Clinically stroke is not suspected\n2. Allergic to the Tetracycline group of medications or Intolerance to Minocycline\n3. Pregnancy or suspected pregnancy or breastfeeding\n4. Previous history of intolerance to Minocycline\n5. Acute or chronic renal failure (stage III with GFR \\*(Glomerular Filtration Rate) \\* or Creatinine threshold)\n6. Any patients with contraindications to undergo CT (Computed Tomography) \u002F MRI (Magnetic Resonance Imaging)\n7. Life expectancy less than one year or severe co-morbidities or comfort measure only (CMO) on admission\n8. Pre-existing infectious disease requiring antibiotics\n9. Inability to tolerate enteral medications\u002Ffeeds\n10. Patient\u002F family refusal","ALL","18 Years",{"count":19,"type":20},1164,"ESTIMATED","INTERVENTIONAL",[23,24],"PHASE2","PHASE3","The goal of this study is to determine if Minocycline, when added to standard care, can improve survival and functional outcomes in patients with moderate acute stroke (ischemic or hemorrhagic) aged 18 years and older.\n\nThe main questions it aims to answer are:\n\n1. Does Minocycline improve \\*National Institutes of Health Stroke Scale\\* (NIHSS) scores at hospital discharge and 90 days post-stroke?\n2. Does Minocycline reduce stroke-related disability, all-cause in hospital mortality (mRS -\\*Modified Rankin Scale\\* = 6) and at 90 days besides reducing brain bleeding complications compared to standard care?\n\nResearchers will compare patients receiving oral Minocycline plus standard care to those receiving standard care only to see if Minocycline leads to better neurological outcomes and lower mortality.\n\nParticipants will:\n\n1. Be randomly assigned by block to receive either:\n\n   Minocycline 200 mg orally once daily for five days within 24 hours from symptoms onset + Standard Care, or Standard Care only\n2. Undergo neurological assessments using NIHSS \\*National Institutes of Health Stroke Scale\\* and Modified Rankin Scale (mRS) at admission, discharge, 30 days post-stroke, 90 days post-stroke\n3. Be monitored for: a) hemorrhagic transformation of ischemic strokes; b) Adverse events and mortality outcomes; c) Safety and efficacy signals through interim analyses\n\nNIHSS: \\*National Institutes of Health Stroke Scale\\*, which is stroke severity scale,\n\nmRS: \\*Modified Rankin Scale\\*, which is stroke disability scale",[27,28,29,30,31,32,33],"Stroke","Ischemia Stroke","Hemorrhagic Strokes","Mortality","Morbidity","Cerebrovascular Accident (Stroke)","Intracerebral Haemorrhage (ICH)",[35,36,37,38,39,40,41,42,43,44,31,30,45,46,47,48],"Minocycline","Acute Stroke","Neuroprotection","Ischemic Stroke","Hemorrhagic Stroke","NIH Stroke Scale","Modified Rankin Scale (mRS)","Stroke Recovery","Stroke Treatment","Stroke Outcomes","Intravenous Thrombolysis","Mechanical Thrombectomy","Hemorrhagic Transformation","Oral antibiotic","RECRUITING","2026-03-18",{"date":52,"type":53},"2026-03-19","ACTUAL",{"date":55,"type":53},"2026-02-02",{"date":57,"type":20},"2028-12",{"name":59,"class":60},"Joyce Chen","OTHER",1,{"id":63,"slug":64,"hasResults":11,"nctId":65,"briefTitle":66,"officialTitle":66,"acronym":67,"eligibilityCriteria":68,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":69,"targetDuration":4,"studyType":21,"phases":71,"briefSummary":73,"conditions":74,"keywords":84,"overallStatus":49,"whyStopped":4,"lastUpdateSubmitDate":95,"lastUpdatePostDateStruct":96,"startDateStruct":98,"completionDateStruct":100,"leadSponsor":102,"locationsCount":61},"100597086","phase-1-psychedelic-healing-adjunct-therapy-harnessing-opened-malleability-100597086","NCT07053917","Psychedelic Healing: Adjunct Therapy Harnessing Opened Malleability","PHATHOM","Inclusion Criteria:\n\n* Over age 18 years, inclusive.\n* Ischemic or hemorrhagic stroke confirmed by CT or MRI, at least 12 months prior to admission date\n* Ability to give informed consent and understand the tasks involved.\n* Agree that, for the study duration, will refrain from: (1) No new prescription medications during the time of the study without approval of the study team, (2) taking any herbal supplement (except with prior approval of the research team), (3) taking any nonprescription medications with the exception of: 1. non-steroidal anti-inflammatory drugs. 2. acetaminophen. 3. vitamins. 4. or other over-the-counter medications approved by the research team\n* Are willing to follow restrictions and guidelines concerning medications, consumption of food, beverages, and nicotine the night before and just prior to psilocybin administration.\n* Agree to have transportation other than driving themselves home or to where the participants are staying after the administration of psilocybin.\n* Are willing to be contacted via telephone for all necessary telephone contacts.\n* Must have a negative pregnancy test if able to bear children.\n* Must provide a contact (relative, spouse, close friend or other caregiver) who is willing and able to be reached by the investigators in the event of a participant becoming suicidal.\n* Must agree to inform the investigators within 48 hours of any new medical conditions and procedures.\n* Are proficient in speaking and reading English.\n* Agree to have all clinical visit sessions recorded to audio and video.\n* Agree to not participate in any other interventional clinical trials during the duration of this study.\n\nExclusion Criteria:\n\n* Taking one of the following medications in the 30 days prior to psilocybin administration:\n\n  1. selective serotonin reuptake inhibitor (SSRI)\n  2. Serotonin-norepinephrine reuptake inhibitors (SNRI)\n  3. Buproprion\n  4. Valproic acid\n  5. Zolpidem\n  6. Trazodone\n  7. Carbamazepine.\n  8. tricyclic antidepressants\n  9. Monoamine Oxidase Inhibitors\n  10. Mirtazapine\n\n  l. Lithium m. Buspirone n. Atypical antipsychotics o. Zolpidem p.Carbamazepine q. Clonazepam r. Gabapentin s. Lamotrigine t. Levetiracetam u. Phenobarbital v. Phenytoin w. Topiramate x. Valproic Acid y. Zonisamide\n* History of medically significant suicide attempt.\n* Evidence of acute cardiac dysfunction as evidenced by either elevated troponin or EKG changes within 48 hours of administration.\n* Systolic blood pressure that is greater than 150 mmHg systolic on \\> 2 readings during the 7-day monitoring period AND blood pressure medication management has been assured.\n* Diastolic blood pressure that is greater than 100 mmHg systolic on \\> 2 readings during the 7-day monitoring period AND blood pressure medication management has been assured.\n* Systolic blood pressure is less than 90 mmHg systolic on \\> 2 readings during the 7-day monitoring period after blood pressure medication management has been assured.\n* Diastolic blood pressure is less than 30 mmHg systolic on \\> 2 readings during the 7-day monitoring period after blood pressure medication management has been assured.\n* Systolic blood pressure exceeds 160 mmHg or is less than 90 mmHg immediately prior to administration of psilocybin; patients are allowed to be on anti-hypertensives.\n* Diastolic blood pressure exceeds 100 mmHg or is less than 30 mmHg immediately prior to administration of psilocybin; patients are allowed to be on anti-hypertensives.\n* Cognitive impairment that, in the estimation of the study team, would preclude the use of the MindPod Dolphin.\n* History of physical or neurological condition that interferes with study procedures or assessment of motor function (e.g. severe arthritis, severe neuropathy, Parkinson's disease).\n* Social and\u002For personal circumstances that interfere with ability to perform follow up assessments.\n* Are pregnant or nursing.\n* Weigh less than 48 kg.\n* Are not able to give adequate informed consent.\n* Are actively abusing opioids, cocaine, Phencyclidine (PCP), amphetamines, or alcohol.\n* Structured Clinical Interview for Diagnostic and Statistical Manual of Mental Disorders (SCID-5) criteria for moderate or severe substance use disorder\n* Diagnosis of schizophrenia, history of prior psychosis, anxiety requiring hospitalization, or Type 1 bipolar.\n* Hypernatremia\n* Hypokalemia (but can have received repletion during the prior 24 hours)\n* Hyperkalemia\n* Glomerular filtration rate of \\\u003C 30 ml\u002Fmin\n* Elevated of white blood cell count\n* Hemoglobin \\\u003C 7 g\u002Fdl\n* Platelet count \\\u003C 100,000 g\u002Fdl\n* Acute cardiac dysfunction demonstrated by either troponin elevation (chronic elevation is acceptable), or EKG changes suggestive of acute coronary syndrome.\n* Active suicidal ideation as assess by the C-SSRS.",{"count":70,"type":20},20,[72],"PHASE1","The main purpose of the current studies is to evaluate the safety and tolerability of psilocybin in patients with chronic stroke.",[27,75,76,33,77,38,78,79,80,81,82,83],"Chronic Stroke","Intracerebral Haemorrhage","Intracerebral Hemorrhage Basal Ganglia","Ischemic Stroke and Hemorrhagic Stroke","Hemiparesis After Stroke","Hemiplegia Following Ischemic Stroke","Hemiplegia and Hemiparesis","Hemiplegia and\u002For Hemiparesis Following Stroke","Middle Cerebral Artery Stroke",[85,86,87,88,89,90,91,92,93,94],"psychedelic","stroke","chronic stroke","intracerebral hemorrhage","stroke recovery","motor recovery","poststroke recovery","poststroke motor recovery","hemiparesis recovery","psychedelic safety","2026-02-11",{"date":97,"type":53},"2026-02-13",{"date":99,"type":53},"2026-02-09",{"date":101,"type":20},"2027-03",{"name":103,"class":60},"Johns Hopkins University",{"id":105,"slug":106,"hasResults":11,"nctId":107,"briefTitle":108,"officialTitle":108,"acronym":4,"eligibilityCriteria":109,"healthyVolunteers":11,"sex":16,"minAge":110,"maxAge":111,"enrollmentInfo":112,"targetDuration":4,"studyType":21,"phases":114,"briefSummary":116,"conditions":117,"keywords":4,"overallStatus":49,"whyStopped":4,"lastUpdateSubmitDate":118,"lastUpdatePostDateStruct":119,"startDateStruct":121,"completionDateStruct":123,"leadSponsor":125,"locationsCount":61},"100578849","surgical-evacuation-of-spontaneous-intracerebral-hematoma-clinical-outcomes-and-prognostic-factors-100578849","NCT06816641","Surgical Evacuation Of Spontaneous Intracerebral Hematoma: Clinical Outcomes and Prognostic Factors","Inclusion Criteria:\n\n* • Patients with radiological findings of ICH.\n\n  * Age group 20-70 years.\n\nExclusion Criteria:\n\n* • Traumatic ICH or ruptured aneurysm or AVM or brain tumor.\n\n  * Postoperative cranial surgery ICH.\n  * Secondary hydrocephalus.\n  * Patients with other comorbidities e.g., Liver cell failure and renal cell failure.\n  * Patients with bleeding disorders.\n  * Patients who are regular on anticoagulant or antiplatelet therapy.\n  * Small sized ICH\\\u003C 30 ml.\n  * GCS less than 6 preoperatively.","20 Years","70 Years",{"count":113,"type":20},40,[115],"NA","The aim of this study is to assess the safety and efficacy of surgical evacuation of spontaneous intracerebral hemorrhage.",[33],"2025-02-07",{"date":120,"type":53},"2025-02-11",{"date":122,"type":53},"2022-01-01",{"date":124,"type":20},"2025-12-30",{"name":126,"class":60},"Sohag University"]